Top 22 R&D Spenders among Tool and Technologies Companies

Figures were disclosed by the companies in forms 10-K or 20-F, filed with the U.S. Securities and Exchange Commission (SEC); corporate annual reports; quarterly results press releases, and S-1 Securities Registration Statements also filed with the SEC. Where applicable, figures were converted to U.S. dollars from other currencies.

Notes:
¹ R&D spending figures converted to USD via XE (www.xe.com) on March 29, 2013.
² Figure reported to one decimal place in March 25 press release announcing selected 2012 results.
³ R&D spending figures converted to USD via XE (www.xe.com) on March 29, 2013.
⁴ Life Sciences & Diagnostics is the segment of Danaher Corp. that provides tools for biopharma research. Danaher’s life sciences business offer research and clinical tools used by scientists to study cells and cell components. Danaher’s diagnostics businesses offer analytical instruments, reagents, consumables, software and services used by hospitals, physician’s offices, reference laboratories and other critical care settings.
⁵ Merck Millipore is the division of Merck KGaA that supplies products and services for the life science industry. Key customer groups include research and analytical laboratories in the pharmaceutical/biotechnology industry or in academic institutions, and manufacturers of large and small molecule drugs.
⁶ R&D spending figures converted to USD via XE (www.xe.com) on March 29, 2013.
⁷ Figure reduced from €134.5 million in 2011 annual report following shift of €1.1 billion for legal, financial and organizational functions to administration expenses.
⁸ BD’s fiscal years encompass the 12 months ending September 30.
⁹ Agilent’s fiscal years encompass the 12 months ending October 31.
¹⁰ Includes GE’s drug discovery and biopharmaceutical manufacturing technologies businesses, as well as businesses focused on medical imaging and information technologies, medical diagnostics, and patient monitoring systems.
¹¹ Figures furnished by company to GEN. The figures vary from two previously published amounts. Last year, FierceMedicalDevices reported that the company’s 2011 R&D budget was $1.3 billion. However, a GE Healthcare presentation from the 4th University Forum in Brussels (March 22, 2011) stated that company R&D spending was “$1.5 billion,” though it was not stated if the figure covered 2011 or 2010.
¹² Includes Roche’s Professional Diagnostics, Tissue Diagnostics, Diabetes Care, and Applied Science businesses.
¹³ R&D spending figures converted to USD via XE (www.xe.com) on March 29, 2013.